Discovery is experimentation. Proving it to an examiner is the hard part.
Most of what a research organization does clears the four-part test on the science. Life-sciences claims are then decided on who funded the program, where the CRO performed the work, and whether the record was written down at the time.
Photo by Julia Koblitz on Unsplash
Why life-sciences R&D qualifies
A new or improved compound, formulation, assay, or process is a business component. Discovery and development inherently involve resolving genuine scientific and technical uncertainty through a systematic process of experimentation - screening, formulating, running assays, and iterating on results - which is precisely what the credit rewards.
Every qualifying activity must pass the IRC §41 four-part test - permitted purpose, technological in nature (the biological and physical sciences), elimination of uncertainty, and a process of experimentation. Much of preclinical and bench science maps to this naturally.
Two facts shape every life-sciences claim. First, audit scrutiny is high, so substantiation must be contemporaneous and organized by business component. Second, the funded-research screen matters: grant- and contract-funded work may be excluded where you don’t bear the risk or retain rights. We screen both before anything is claimed.
Seven things that happened at the bench last year
Not activity categories - situations. If any of these read like a program you actually ran, there is very likely a qualified business component underneath it.
-
“The assay could not separate signal from background.”
Buffers, blocking agents, and two detection chemistries were screened before the window opened wide enough to call a hit.
Why it can qualify: Method uncertainty resolved by systematic screening - the plainest possible example of a process of experimentation.
-
“The API crashed out of solution at 4 °C.”
Excipient systems and solubilization approaches were formulated and placed on stability until one held through the study period.
Why it can qualify: Formulation development against a requirement that could not be predicted from first principles.
-
“An impurity co-eluted with the main peak.”
Column chemistries and gradient profiles were developed and validated until the method resolved both species reproducibly.
Why it can qualify: Analytical method development relies on the physical sciences and starts from genuine uncertainty about the appropriate design.
-
“Titer plateaued at two grams per liter.”
Media, feed strategy, and bioreactor conditions were explored in a designed experiment across several runs.
Why it can qualify: Process development for a bioprocess business component. A DoE is a documented, systematic evaluation of alternatives.
-
“The polish step lost 40% of the yield.”
Resins and buffer conditions were screened at small scale before the change was ever taken into the suite.
Why it can qualify: Purification process development - and the resins, media, and plasticware consumed in the screen are supply QREs.
-
“It behaved differently at 200 L than it had at 10 L.”
Mixing, oxygen transfer, and shear were re-engineered and re-tested until the larger scale reproduced the small-scale result.
Why it can qualify: Scale-up uncertainty is real technical uncertainty, not a manufacturing formality - and the scaled process is its own business component.
-
“The mechanism question had to be answered before dosing.”
In vitro work and a dose-ranging design were run specifically to resolve it, with the protocol amended once on the data.
Why it can qualify: Preclinical work resolving a scientific question about safety, efficacy, or mechanism. Clinical-stage activities are analyzed one at a time, on their facts.
Illustrative situations, not client work. Whether any of them qualifies for you depends on your facts, your funding agreements, and your evidence.
Contemporaneous, or it is an assertion
Life-sciences work clears the science easily and then turns on the record: notebook entries, protocol versions, assay qualification runs, the batch that failed and the reason it failed. Written at the time, that record is evidence. Reconstructed at filing time, it is an assertion.
We pull it alongside the funding agreements and the CRO statements of work, because grant terms, partner milestones, and the site where the work was actually performed decide these claims more often than the biology does.
The life-sciences work that commonly qualifies
Representative activities we see meet the four-part test across discovery, development, and process science.
Drug discovery
Formulation
Assay development
Analytical method development
Preclinical studies
Qualifying clinical-stage activities
Bioprocess & scale-up
Regulatory-driven experimentation
Computational modeling
Typical QRE categories for life sciences
What spending counts toward the credit - tailored to how research organizations actually spend.
| Expense category | What goes into the base |
|---|---|
| Scientist & technician wages§41(b)(2)(A)-(B) | Wages for scientists and technicians performing, supervising, or directly supporting qualified research. |
| Contract research / CRO (65%)§41(b)(3) | 65% of amounts paid to U.S. CROs and contract researchers for qualified research performed on your behalf. |
| Reagents & lab consumables§41(b)(2)(C) | Reagents, media, and lab consumables used up in qualified research - not depreciable instruments. |
| Cloud & compute§41(b)(2)(A)(iii) | Amounts paid to rent compute for modeling, simulation, and data analysis used in qualified research. |
What the base usually looks like
IllustrativeA directional shape for a research organization, not a benchmark. Life sciences is the one industry where outsourced research can rival internal payroll - and where its geography quietly decides the number.
- Scientist & technician wages - Bench scientists, technicians, and the research leadership directly supervising them.
- 44%
- U.S. contract research (CRO) - Included at 65% of amounts paid - and only where the work was performed in the U.S.
- 30%
- Reagents & consumables - Media, reagents, antibodies, resins, and plasticware consumed in research.
- 24%
- Cloud & compute - Rented capacity for modeling, simulation, and analysis.
- 2%
The funded-research screen - §41(d)(4)(H)
Research paid for by a grant or contract under which you don’t bear the financial risk or retain substantial rights is generally excluded. The funding terms and the rights-and-risk analysis are decisive.
In practice that means reading the award letter, the collaboration agreement, and the CRO master services agreement - including the IP and data-rights clauses and whether payment was contingent on the science working. A study that skips this step is an examination waiting to happen.
The provision written for a company with no income to shelter
A clinical-stage biotech with a large research payroll and no revenue is the exact profile §41(h) was written for. A qualified small business may elect to apply up to $500,000 of research credit per year against payroll taxes instead of income tax - the employer share of Social Security tax first, and the Medicare share above that - turning a credit you could not otherwise use into quarterly cash.
The definition is where otherwise-eligible companies fall out. It requires gross receipts under $5 million for the credit year and no gross receipts before the five-year window ending in that year, so an early collaboration payment or a small grant recorded as revenue six years ago can close the door. The election is made on a timely-filed return, claimed on Form 8974 with your quarterly employment tax return, and cannot be made for more than five tax years.
Rough QSB screen
- Gross receipts under $5M in the credit year
- No gross receipts before the five-year window ending in that year
- A real U.S. payroll to offset
- Election made on a timely-filed return, not after the fact
- Five tax years is the maximum, ever
Summary only - the statutory definition and the aggregation rules decide it. We test them explicitly.
What a biotech study can look like
A hypothetical scenario to show how the pieces fit together. It is not a quote, projection, or promise of results.
- Research payroll
- $4M
- Share qualified
- ~70%
- Reagents & consumables
- $1.2M
- U.S. CRO work
- $2M
- Estimated QRE
- ~$5.3M
- Illustrative federal credit
- ≈ $320K-$530K
On these facts the first question is not the size of the credit but whether the §41(h) election is available - up to $500,000 of it could come back as payroll-tax cash rather than a carryforward.
Illustrative only. Figures are hypothetical and rounded; CRO work is included at 65% and assumes no funded-research exclusion applies. The federal credit commonly works out to roughly 6-10% of QRE depending on method, filing history, and the §280C election. Your result depends entirely on your facts. This is not a quote or a guarantee.
Domestic research is fully deductible again
IRC §174A restores immediate, full expensing of domestic research & experimental costs for tax years beginning after December 31, 2024 - including qualified domestic discovery and development. Captured alongside the §41 credit, you get the deduction and the credit.
Pharma & biotech - frequently asked questions
Do CRO and contract research costs count?
Does clinical work qualify?
What about grant-funded research?
We’re pre-revenue and clinical-stage. Is there any cash in this?
How do you defend a claim given high audit scrutiny?
Do reagents and lab consumables count?
Does §174A apply to our domestic R&E?
Can we claim prior years we already filed?
How much does the calculation method change the number?
Next
Documentation and substantiation, including Form 6765
What a business-component narrative has to contain, and what the IRS asks for on a refund claim.
Also relevant
Bioprocess scale-up and fill-finish development are process business components; the manufacturing page carries that vocabulary.